Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Ruthenium-106 Plaque Radiotherapy for Uveal Melanoma: Analysis of Tumor Dimension and Location on Anatomical and Functional Results Publisher Pubmed



Mirshahi R1 ; Sedaghat A1 ; Jaberi R2 ; Azma Z3 ; Mazloumi M1 ; Naseripour M1, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Eye Research Center, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Cancer Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Radiation Medicine Department, Shahid Beheshti University, Tehran, Iran
  4. 4. Stem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran

Source: BMC Ophthalmology Published:2022


Abstract

Background: To report the long-term outcomes of Ru-106 plaque radiotherapy in eyes with uveal melanoma (UM) and to assess the effect of tumor thickness and location on final outcomes. Methods: Medical records of 234 patients undergoing Ru-106 plaque radiotherapy for UM were reviewed, and the visual outcome, globe preservation, and patient survival were evaluated. The results of 2 groups were compared: 1. between thin (small and medium-sized, thickness < 7 mm, 148 eyes [63.2%]) and thick (thickness ≥ 7 mm, 86 eyes [36.8%]) tumors, and 2. between large (largest basal diameter [LBD] > 12 mm, 109 eyes [46.6%]) and medium/small (LBD ≤ 12 mm, 125 eyes [53.4%]). In addition, a comparison of the juxtapapillary location in 46 eyes (19.7%) versus tumors arising elsewhere and between tumors with and without ciliary involvement in 48 eyes (21.5%) were done. Results: The patients were followed for a median of 54.2 months (range: 6–194.5 months). After adjusting for baseline visual acuity (VA), there was no significant association between final VA and different dimension and tumor location groups. Final globe preservation was 91.9%, and there was no significant difference between different dimension- and ciliary body involvement groups regarding anatomical success rate. The juxtapapillary tumors had lower globe preservation (80.4% vs.94.7%, p = 0.002). The hazard ratio (HR) for enucleation in juxtapapillary tumors was HR = 6.58 (95-CI: 3.84 to 11.21). The overall metastasis rate was 6.8%, with no significant difference in juxtapapillary tumors (4.3% vs.7.4%, p = 0.455). Conclusions: Ru-106 plaque radiotherapy is an effective treatment for thick and large UM. With this type of treatment, the globe preservation rate is lower in juxtapapillary tumors, but there is no significant difference in the metastasis rate. © 2022, The Author(s).
Related Docs
1. Ruthenium-106 Brachytherapy for Thick Uveal Melanoma: Reappraisal of Apex and Base Dose Radiation and Dose Rate, Journal of Contemporary Brachytherapy (2016)
2. Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas, Clinical Ophthalmology (2020)
3. Uveal Melanoma in the Iranian Population: Two Decades of Patient Management in a Tertiary Eye Center, International Journal of Retina and Vitreous (2024)
4. Corneal Patch Graft: A New Approach for Scleral Necrosis Secondary to Plaque Radiotherapy, Cornea (2016)
5. On Measuring the 3D Dose Distribution for Notched and Circular Ru-106 Plaque Shapes Through Gafchromic Film Dosimetry Approach, Radiation Physics and Chemistry (2022)
Experts (# of related papers)
View all Related Experts
Fariba Ghassemi (2)
Elias Khalilipour (1)